NCGC607   Click here for help

GtoPdb Ligand ID: 10697

Synonyms: KUC107647N [1] | NCGC00241607
Compound class: Synthetic organic
Comment: NCGC607 is a glucocerebrosidase (GCase) chaperone [1]. Unlike ambroxol, it does not occlude the enzyme active site so is not predicted to inhibit GCase activity. Enhancement of lysosomal GCase activity using chaperone molecules is being explored in diseases that are associated with mutant GCase GBA1, such as the lysosomal storage disorder Gaucher disease, and the neurodegenerative synucleinopathies Parkinson's disease and dementia with Lewy bodies. Enhanced GCase activity is predicted to prevent aggregation of neurotoxic proteins or improve the clearance of protein aggregates. This mechanism is considered to be applicable to a number of age-related neurodegenerative disorders that are characterised by aggregates of misfolded, non-functional and neurotoxic proteins [2]. Under experimental conditions, NCGC607 restores GCase activity and protein levels, and reduces glycolipid storage in Gaucher macrophages, and reduces α-synuclein levels in dopaminergic neurons from Parkinson's patients [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 87.74
Molecular weight 543.07
XLogP 4.03
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(Nc1ccc(cc1)I)COc1ccccc1C(=O)NCC(=O)N(c1ccccc1)C
Isomeric SMILES O=C(Nc1ccc(cc1)I)COc1ccccc1C(=O)NCC(=O)N(c1ccccc1)C
InChI InChI=1S/C24H22IN3O4/c1-28(19-7-3-2-4-8-19)23(30)15-26-24(31)20-9-5-6-10-21(20)32-16-22(29)27-18-13-11-17(25)12-14-18/h2-14H,15-16H2,1H3,(H,26,31)(H,27,29)
InChI Key HFVDMJQQAKLUSN-UHFFFAOYSA-N
References
1. Aflaki E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patnaik S, Schoenen FJ, Westbroek W, Zheng W, Sullivan P et al.. (2016)
A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
J Neurosci, 36 (28): 7441-52. [PMID:27413154]
2. Boland B, Yu WH, Corti O, Mollereau B, Henriques A, Bezard E, Pastores GM, Rubinsztein DC, Nixon RA, Duchen MR et al.. (2018)
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.
Nat Rev Drug Discov, 17 (9): 660-688. [PMID:30116051]